195 related articles for article (PubMed ID: 29625497)
21. Expression of aberrant beta-catenin and impaired p63 in craniopharyngiomas.
Cao J; Lin JP; Yang LX; Chen K; Huang ZS
Br J Neurosurg; 2010 Jun; 24(3):249-56. PubMed ID: 20128632
[TBL] [Abstract][Full Text] [Related]
22. Correlations between the expression of molecules in the TGF-β signaling pathway and clinical factors in adamantinomatous craniopharyngiomas.
Jin L; Cai K; Wu W; Xiao Y; Qiao N; Liu F; Ru S; Cao L; Zhu H; Bai J; Liu C; Li C; Zhao P; Zhang Y; Gui S
Front Endocrinol (Lausanne); 2023; 14():1167776. PubMed ID: 37854185
[TBL] [Abstract][Full Text] [Related]
23. Expression of Wnt4 in human pituitary adenomas regulates activation of the beta-catenin-independent pathway.
Miyakoshi T; Takei M; Kajiya H; Egashira N; Takekoshi S; Teramoto A; Osamura RY
Endocr Pathol; 2008; 19(4):261-73. PubMed ID: 19034702
[TBL] [Abstract][Full Text] [Related]
24. Telomere length and Wnt/β-catenin pathway in adamantinomatous craniopharyngiomas.
Mota JIS; Silva-Júnior RMP; Martins CS; Bueno AC; Wildemberg LE; Antunes XLDS; Ozaki JGO; Coeli-Lacchini FB; Garcia-Peral C; Oliveira AER; Santos AC; Moreira AC; Machado HR; Dos Santos MV; Colli LM; Gadelha MR; Antonini SRR; de Castro M
Eur J Endocrinol; 2022 Jun; 187(2):219-230. PubMed ID: 35584004
[TBL] [Abstract][Full Text] [Related]
25. Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma.
Coy S; Rashid R; Lin JR; Du Z; Donson AM; Hankinson TC; Foreman NK; Manley PE; Kieran MW; Reardon DA; Sorger PK; Santagata S
Neuro Oncol; 2018 Jul; 20(8):1101-1112. PubMed ID: 29509940
[TBL] [Abstract][Full Text] [Related]
26. Differential Expression of Stem Cell Markers in Human Adamantinomatous Craniopharyngioma and Pituitary Adenoma.
Chang CV; Araujo RV; Cirqueira CS; Cani CM; Matushita H; Cescato VA; Fragoso MC; Bronstein MD; Zerbini MC; Mendonca BB; Carvalho LR
Neuroendocrinology; 2017; 104(2):183-193. PubMed ID: 27161333
[TBL] [Abstract][Full Text] [Related]
27. Investigation of N-cadherin/β-catenin expression in adrenocortical tumors.
Rubin B; Regazzo D; Redaelli M; Mucignat C; Citton M; Iacobone M; Scaroni C; Betterle C; Mantero F; Fassina A; Pezzani R; Boscaro M
Tumour Biol; 2016 Oct; 37(10):13545-13555. PubMed ID: 27468715
[TBL] [Abstract][Full Text] [Related]
28. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
[TBL] [Abstract][Full Text] [Related]
29. Characterization of novel CTNNB1 mutation in Craniopharyngioma by whole-genome sequencing.
He J; Zeng Z; Wang Y; Deng J; Tang X; Liu F; Huang J; Chen H; Liang R; Zan X; Liu Z; Tong A; Guo G; Xu J; Zhu X; Zhou L; Peng Y
Mol Cancer; 2021 Dec; 20(1):168. PubMed ID: 34922552
[TBL] [Abstract][Full Text] [Related]
30. Common mutations of beta-catenin in adamantinomatous craniopharyngiomas but not in other tumours originating from the sellar region.
Buslei R; Nolde M; Hofmann B; Meissner S; Eyupoglu IY; Siebzehnrübl F; Hahnen E; Kreutzer J; Fahlbusch R
Acta Neuropathol; 2005 Jun; 109(6):589-97. PubMed ID: 15891929
[TBL] [Abstract][Full Text] [Related]
31. 60 YEARS OF NEUROENDOCRINOLOGY: Biology of human craniopharyngioma: lessons from mouse models.
Martinez-Barbera JP
J Endocrinol; 2015 Aug; 226(2):T161-72. PubMed ID: 25926515
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical expression of ErbB2 in adamantinomatous craniopharyngiomas: a possible target for immunotherapy.
Zuhur SS; Tanik C; Erol RS; Musluman AM; Kabukcuoglu F; Altuntas Y
Turk Neurosurg; 2013; 23(1):55-60. PubMed ID: 23344868
[TBL] [Abstract][Full Text] [Related]
33. Genomic Alterations of Adamantinomatous and Papillary Craniopharyngioma.
Goschzik T; Gessi M; Dreschmann V; Gebhardt U; Wang L; Yamaguchi S; Wheeler DA; Lauriola L; Lau CC; Müller HL; Pietsch T
J Neuropathol Exp Neurol; 2017 Feb; 76(2):126-134. PubMed ID: 28069929
[TBL] [Abstract][Full Text] [Related]
34. Subtype-specific alterations of the Wnt signaling pathway in breast cancer: clinical and prognostic significance.
Mukherjee N; Bhattacharya N; Alam N; Roy A; Roychoudhury S; Panda CK
Cancer Sci; 2012 Feb; 103(2):210-20. PubMed ID: 22026417
[TBL] [Abstract][Full Text] [Related]
35. Activation of the Wnt/β-catenin pathway is common in wilms tumor, but rarely through β-catenin mutation and APC promoter methylation.
Schweigert A; Fischer C; Mayr D; von Schweinitz D; Kappler R; Hubertus J
Pediatr Surg Int; 2016 Dec; 32(12):1141-1146. PubMed ID: 27679509
[TBL] [Abstract][Full Text] [Related]
36. TREM-1 expression in craniopharyngioma and Rathke's cleft cyst: its possible implication for controversial pathology.
Liu Y; Wang CH; Li DL; Zhang SC; Peng YP; Peng JX; Song Y; Qi ST; Pan J
Oncotarget; 2016 Aug; 7(31):50564-50574. PubMed ID: 27409178
[TBL] [Abstract][Full Text] [Related]
37. BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma.
Larkin SJ; Preda V; Karavitaki N; Grossman A; Ansorge O
Acta Neuropathol; 2014; 127(6):927-9. PubMed ID: 24715106
[No Abstract] [Full Text] [Related]
38. Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target.
Apps JR; Carreno G; Gonzalez-Meljem JM; Haston S; Guiho R; Cooper JE; Manshaei S; Jani N; Hölsken A; Pettorini B; Beynon RJ; Simpson DM; Fraser HC; Hong Y; Hallang S; Stone TJ; Virasami A; Donson AM; Jones D; Aquilina K; Spoudeas H; Joshi AR; Grundy R; Storer LCD; Korbonits M; Hilton DA; Tossell K; Thavaraj S; Ungless MA; Gil J; Buslei R; Hankinson T; Hargrave D; Goding C; Andoniadou CL; Brogan P; Jacques TS; Williams HJ; Martinez-Barbera JP
Acta Neuropathol; 2018 May; 135(5):757-777. PubMed ID: 29541918
[TBL] [Abstract][Full Text] [Related]
39. Rab11a sustains GSK3β/Wnt/β-catenin signaling to enhance cancer progression in pancreatic cancer.
Yu L; Li X; Li H; Chen H; Liu H
Tumour Biol; 2016 Oct; 37(10):13821-13829. PubMed ID: 27481517
[TBL] [Abstract][Full Text] [Related]
40. Genetic polymorphisms in the Wnt/β-catenin pathway genes as predictors of tumor development and survival in patients with hepatitis B virus-associated hepatocellular carcinoma.
Kim SS; Cho HJ; Lee HY; Park JH; Noh CK; Shin SJ; Lee KM; Yoo BM; Lee KJ; Cho SW; Cheong JY
Clin Biochem; 2016 Jul; 49(10-11):792-801. PubMed ID: 26968103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]